These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 28131754

  • 21. Cyclosporine release and distribution in ophthalmic emulsions determined by pulsatile microdialysis.
    Bellantone RA, Shah KB, Patel PG, Kaplan M, Xu X, Li V, Newman B, Abul Kaisar M.
    Int J Pharm; 2022 Mar 05; 615():121521. PubMed ID: 35093461
    [Abstract] [Full Text] [Related]

  • 22. [Cyclosporine 2% eye drops preparation].
    Chast F, Lemare F, Legeais JM, Batista R, Bardin C, Renard G.
    J Fr Ophtalmol; 2004 Jun 05; 27(6 Pt 1):567-76. PubMed ID: 15343115
    [Abstract] [Full Text] [Related]

  • 23. Asymmetric flow field flow fractionation for the characterization of globule size distribution in complex formulations: A cyclosporine ophthalmic emulsion case.
    Qu H, Wang J, Wu Y, Zheng J, Krishnaiah YSR, Absar M, Choi S, Ashraf M, Cruz CN, Xu X.
    Int J Pharm; 2018 Mar 01; 538(1-2):215-222. PubMed ID: 29341918
    [Abstract] [Full Text] [Related]

  • 24. Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits.
    Parrilha LR, Nai GA, Giuffrida R, Barbero RC, Padovani LD, Pereira RH, Silva DA, Silva MC, Diniz MS, Andrade SF.
    Arq Bras Oftalmol; 2015 Mar 01; 78(5):295-9. PubMed ID: 26466228
    [Abstract] [Full Text] [Related]

  • 25. Phospholipid-stabilized nanoparticles of cyclosporine A by rapid expansion from supercritical to aqueous solution.
    Young TJ, Johnson KP, Pace GW, Mishra AK.
    AAPS PharmSciTech; 2004 Feb 17; 5(1):E11. PubMed ID: 15198532
    [Abstract] [Full Text] [Related]

  • 26. Investigations on the lyophilisation of MPEG-hexPLA micelle based pharmaceutical formulations.
    Di Tommaso C, Como C, Gurny R, Möller M.
    Eur J Pharm Sci; 2010 Apr 16; 40(1):38-47. PubMed ID: 20184955
    [Abstract] [Full Text] [Related]

  • 27. Physicochemical stability study on cyclosporine A loaded dry-emulsion formulation with enhanced solubility.
    Sato H, Ogawa K, Kojo Y, Suzuki H, Mizumoto T, Onoue S.
    Chem Pharm Bull (Tokyo); 2015 Apr 16; 63(1):54-8. PubMed ID: 25743195
    [Abstract] [Full Text] [Related]

  • 28. Improved extemporaneous formulation of cyclosporine ophthalmic drops.
    Mueller DW.
    Am J Hosp Pharm; 1994 Dec 15; 51(24):3080-1. PubMed ID: 7856631
    [No Abstract] [Full Text] [Related]

  • 29. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
    Di Tommaso C, Bourges JL, Valamanesh F, Trubitsyn G, Torriglia A, Jeanny JC, Behar-Cohen F, Gurny R, Möller M.
    Eur J Pharm Biopharm; 2012 Jun 15; 81(2):257-64. PubMed ID: 22445900
    [Abstract] [Full Text] [Related]

  • 30. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing cefazolin.
    Kodym A, Zawisza T, Buźka K, Kukuła H.
    Acta Pol Pharm; 2006 Jun 15; 63(3):225-34. PubMed ID: 20085229
    [Abstract] [Full Text] [Related]

  • 31. Stability of cefepime in aqueous eye drops.
    Kodym A, Pawłowska M, Rumiński JK, Bartosińska A, Kieliba A.
    Pharmazie; 2011 Jan 15; 66(1):17-23. PubMed ID: 21391430
    [Abstract] [Full Text] [Related]

  • 32. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing ceftazidime.
    Kodym A, Zawisza T, Napierała B, Kukuła H.
    Acta Pol Pharm; 2006 Jan 15; 63(6):507-13. PubMed ID: 17438868
    [Abstract] [Full Text] [Related]

  • 33. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis.
    Bozdağ S, Gümüş K, Gümüş O, Unlü N.
    Eur J Pharm Biopharm; 2008 Sep 15; 70(1):260-9. PubMed ID: 18590953
    [Abstract] [Full Text] [Related]

  • 34. Technology of stable, prolonged-release eye-drops containing Cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM).
    Wolska E, Sznitowska M.
    Int J Pharm; 2013 Jan 30; 441(1-2):449-57. PubMed ID: 23164704
    [Abstract] [Full Text] [Related]

  • 35. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels.
    Kapoor Y, Chauhan A.
    Int J Pharm; 2008 Sep 01; 361(1-2):222-9. PubMed ID: 18577433
    [Abstract] [Full Text] [Related]

  • 36. Compatibility of cyclosporine with fat emulsion.
    Jacobson PA, Maksym CJ, Landvay A, Weiner N, Whitmore R.
    Am J Hosp Pharm; 1993 Apr 01; 50(4):687-90. PubMed ID: 8470685
    [Abstract] [Full Text] [Related]

  • 37. [Cyclosporine eye drops: A 4-year retrospective study (2009-2013)].
    Kauss Hornecker M, Charles Weber S, Brandely Piat ML, Darrodes M, Jomaa K, Chast F.
    J Fr Ophtalmol; 2015 Oct 01; 38(8):700-8. PubMed ID: 26371985
    [Abstract] [Full Text] [Related]

  • 38. Comment on "Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion".
    Gore A, Attar M, Pujara C, Neervannan S.
    Mol Pharm; 2014 Jul 07; 11(7):2490-2. PubMed ID: 24803420
    [No Abstract] [Full Text] [Related]

  • 39. Impact of deep freezing on the stability of 25 mg/ml vancomycin ophthalmic solutions.
    Sautou-Miranda V, Libert F, Grand-Boyer A, Gellis C, Chopineau J.
    Int J Pharm; 2002 Mar 02; 234(1-2):205-12. PubMed ID: 11839451
    [Abstract] [Full Text] [Related]

  • 40. [Development of formulation of hipromellose eye drops (artificial tears)].
    Inkeniene AM, Klimas R, Briedis V, Maciulevicius J.
    Medicina (Kaunas); 2003 Mar 02; 39(1):77-82. PubMed ID: 12576769
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.